Axol Bioscience uses human iPSCs to create physiologically relevant in vitro models for neurodegenerative diseases and cardiotoxicity. Their models provide better early-stage modeling and safety testing, as well as improved efficacy evaluation and patient selection. By using their data, clients can de-risk projects, reduce costs, and save time in drug development.